C
Cora N. Sternberg
Researcher at Cornell University
Publications - 747
Citations - 57991
Cora N. Sternberg is an academic researcher from Cornell University. The author has contributed to research in topics: Prostate cancer & Cancer. The author has an hindex of 92, co-authored 663 publications receiving 48986 citations. Previous affiliations of Cora N. Sternberg include CTO Hospital & North Shore University Hospital.
Papers
More filters
Journal ArticleDOI
External Validation of the Association of Progression-Free Survival at 6 Months (PFS6) with Overall Survival at 12 Months (OS12) in Second-Line Therapy for Advanced Urothelial Carcinoma (UC)
Guru Sonpavde,Benjamin L. Maughan,Kenneth M. Boucher,Ronan Fougeray,Toni K. Choueiri,Guenter Niegisch,Y.-N. Wong,Srikala S. Sridhar,Cora N. Sternberg,Joaquim Bellmunt +9 more
TL;DR: PFS6 is robustly associated with OS12 at the trial and individual levels in the setting of second-line therapy for advanced UC, suggesting that PFS6 may be a more optimal endpoint to capture the durable benefits of agents.
Journal ArticleDOI
Somatic and germline sequencing in genitourinary oncology: genetics for the clinician
TL;DR: Next-generation sequencing is becoming a valuable tool in caring for patients with genitourinary malignancies and performing both somatic and germline sequencing will likely become standard practice.
Journal ArticleDOI
A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic (M0) castration-resistant prostate cancer (CRPC): Results of PROSPER by age and region
Karim Fizazi,Maha Hussain,Fred Saad,N.D. Shore,U. De Giorgi,Eleni Efstathiou,Ubirajara Ferreira,Petro Ivashchenko,Katarzyna Madziarska,Mohammed Al-Adhami,Katharina Modelska,De Phung,Joyce Steinberg,Cora N. Sternberg +13 more
Journal ArticleDOI
Clinical outcomes according to PD-L1 status and age in the prospective international SAUL study of atezolizumab (atezo) for locally advanced or metastatic urothelial carcinoma (UC) or non-UC of the urinary tract.
Cora N. Sternberg,Axel S. Merseburger,Ernest Choy,Daniel Castellano,Fernando Lopez-Rios,Nicholas D. James,Giuseppe Luigi Banna,Ugo De Giorgi,Cristina Masini,Aristotelis Bamias,Xavier Garcia del Muro,Thomas Powles,Ignacio Duran,Craig Gedye,Marija Gamulin,Friedemann Zengerling,Lajos Géczi,Sabine de Ducla,Simon Fear,Yohann Loriot +19 more
TL;DR: Atezo, a monoclonal antibody targeting PD-L1, is an approved therapy for locally advanced/metastatic UC based on IMvigor210 and IMvatory211 phase II and III trials.